Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Standard Precaution01:26

Standard Precaution

Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabis Is Associated With Potentially Proatherogenic Inflammation in Youth.

Circulation research·2026
Same author

<i>Ex vivo</i> modeling of nasal epithelial airway inflammation in respiratory viral infections.

Frontiers in microbiology·2026
Same author

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. Reply.

The New England journal of medicine·2026
Same author

Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review and meta-analysis.

PLoS medicine·2026
Same author

Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jun 3, 2026

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Preexposure prophylaxis for HIV prevention.

Theodoros Kelesidis1, Raphael J Landovitz

  • 1Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Current HIV/AIDS Reports
|April 6, 2011
PubMed
Summary

Preexposure prophylaxis (PrEP) shows promise for preventing HIV infections, with initial success in men who have sex with men (MSM). Further research is needed to confirm effectiveness in other groups and address implementation challenges.

More Related Videos

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

Related Experiment Videos

Last Updated: Jun 3, 2026

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

Area of Science:

  • Public Health
  • Infectious Diseases
  • HIV Prevention

Background:

  • Reducing HIV incidence is a major global public health priority.
  • Preexposure prophylaxis (PrEP) is an emerging strategy with potential to significantly impact HIV prevention.
  • Oral PrEP has demonstrated proof-of-principle in preventing HIV among men who have sex with men (MSM).

Purpose of the Study:

  • To review the potential strengths and limitations of PrEP for HIV prevention.
  • To identify challenges hindering the implementation of PrEP.
  • To outline existing knowledge gaps regarding PrEP.

Main Methods:

  • Review of recently presented data on oral PrEP use in MSM.
  • Analysis of ongoing clinical trials evaluating PrEP in diverse risk groups.
  • Synthesis of information on PrEP's efficacy, safety, adherence, cost, drug resistance, access, and behavioral effects.

Main Results:

  • PrEP has shown effectiveness in preventing HIV in MSM.
  • Ongoing trials are assessing PrEP's efficacy in heterosexual individuals and injection drug users.
  • Several critical questions remain regarding optimal use and implementation.

Conclusions:

  • PrEP is a promising HIV prevention strategy with demonstrated success in specific populations.
  • Further research is essential to address optimal dosing, long-term safety, adherence, cost-effectiveness, and access.
  • Successful implementation of PrEP requires overcoming identified challenges and filling knowledge gaps.